comprehensive -WSS

comprehensive

author：focus 2025-09-01 06:02:56 - browse：61

Illumina building. -- biotech coverage from STAT — Adobe

LONDON — The European Union on Wednesday issued an antitrust fine of $475 million to the U.S. genetic sequencing giant Illumina for closing its acquisition of cancer detection company Grail before clearing it with regulators.

The fine amounts to nearly 10% of Illumina’s annual global revenue, which is the most the European Commission can penalize a company under its merger regulations. The commission called Illumina’s actions “an unprecedented and very serious infringement” of the EU’s policies, including the “cornerstone” that regulators review deals that can alter the market.

The commission also issued what it called a symbolic fine of 1,000 Euros, or about $1,100, to Grail for what it said was the firm’s “active role” in the deal’s infringement of EU rules.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： What a koala virus tells us about the human genome

hotspot

WSS

WuXi Biologics execs register to lobby as Congress comes for the company

Families look for replacement for GSK asthma drug Flovent

Hottest summer in 2,000 years puts focus on extreme heat, health

WuXi Biologics execs register to lobby as Congress comes for the company

STAT reporters are Pulitzer Prize finalists for investigative reporting

Novo Nordisk testing Wegovy against alcohol

hotspot

comprehensive

hotspot

Hollywood unions extend contract negotiations for actors

Obesity drug from Roche shows promise in early study

Affirmative action in medical school literally saved lives

Supreme Court to hear if Covid misinformation is protected speech

United colonoscopy coverage change 'may cost lives,' doctors say

Free medical tuition alone isn't enough to close gaps in primary care

Guidelines to prevent youth baseball injuries need more muscle

Change Healthcare: What is it, why does its cyberattack matter?

23andMe had bad news about my health. I wish a person had delivered it

He's 19 months old and has one of the world’s rarest diseases

leisure time

State of the Union pitch: Bigger Medicare drug price negotiations

CVS is willing to dump 10% of its Medicare Advantage members

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

The public health thinking behind the CDC’s new Covid guidance

For AI in health care standards, federal regulators join with industry group

HHS suspends federal funding for EcoHealth Alliance

knowledge

hotspot

hotspot

entertainment